Jim Strattman

[Amanda Hollensbe (Braelyn’s Mom) @HollensbeAmanda]

Target!!! You are absolutely correct. I am not most parents (and most doctors don’t like that). I have been fighting the system since she was first diagnosed - good thing, too because the system told us she’d be dead 2 and a half years ago. I’m sorry that you know how hard this fight is, too. The system needs to change.

[Jim Strattman @jstrattman]

@AttyScott @MDendream @hoffmann6383 @ElvirPons I agree. I wish someone could find out if this is LSE stuff is something legitimate or just tin foil hat woo woo

[Jim Strattman @jstrattman]

@AttyScott @hoffmann6383 @MDendream @ElvirPons This makes the most sense. They get the first domino to fall & then ratchet up the amount for each lesser defendant they can peel off until they have a war chest to attack the big three along with possible cooperation from lesser defendants. Amounts undisclosed only helps NWBO.

[Jim Strattman @jstrattman]

@CscottLawyer Does that make sense? If they knew approval was pending they‘d just easily raise a ton of money & that information would leak out & the stock would almost certainly reflect a run up. I think they have no idea what the MHRA are doing unless it’s more RFIs & they aren’t telling us.

[Jim Strattman @jstrattman]

@CAgovernor https://t.co/Qg9d0H12Wx

[alphavestcapital.com @alphavestcap]

@alphavestcap

Can the 850 day old dc vax L maa application be moved along toward the finish line ?

https://t.co/9P0ccx2hku

CLAUDE: DOES DR ANNALISA JENKINS CURRENTLY HAVE AN ADVISORY ROLE WTH THE MHRA, OR DOES SHE HAVE RELATIONSHIPS WITH MHRA EMPLOYEES WHEREBY SHE COULD INFLUENCE THEIR DECISION MAKING ?

Claude responded: Based on my research from the previous search, I can give you a clear answer:Based on my research from the previous search, I can give you a clear answer:
No formal MHRA advisory role. Dr. Jenkins does not appear in any MHRA advisory body, committee, or board. The March 2025 MHRA Board Declarations of Interest document — which lists all declared relationships — contains no mention of her.
Her regulatory advisory role is with the FDA, not the MHRA. She sits on the Science Board to the U.S. Food & Drug Administration, which is a completely separate organisation.
On potential informal influence: This is harder to establish or rule out from public records, but a few things are worth noting:

She is a prominent figure in UK life sciences and has publicly commented on MHRA leadership and strategy, including praising the appointment of Lawrence Tallon as MHRA CEO in 2025. This reflects engagement as an industry commentator, not a formal insider role.
She holds positions at Genomics England and previously at The King's Fund — both of which interact with the UK health regulatory ecosystem — but neither gives her a direct line into MHRA decision-making.
She was honoured with an OBE for contributions to life sciences, suggesting she operates at senior levels of the UK health establishment where informal networking with regulators is commonplace across the industry.

Important caveat: Informal relationships between senior industry figures and regulators are rarely documented publicly. If you have a specific regulatory decision or conflict of interest concern in mind, the appropriate routes to investigate further would be:

The MHRA's published registers of interests at https://t.co/DbAHDQwDeC
A Freedom of Information (FOI) request to the MHRA
The MHRA's expert advisory group membership lists, which are publicly available

Is there a specific context or concern driving this question? That might help me give you a more targeted answer.

https://t.co/bWKRQofLIy

[Jim Strattman @jstrattman]

@d_stock07734 Grok:
Replacing Provenge w/ NWBO DCVax-Prostate (PSMA-loaded autologous DC vaccine) + IL-7 could be better. Early data: ~38.7 mo median OS & 64% 3-yr survival vs Provenge's ~25.8 mo & ~34%. PSMA is a strong target; +IL-7's T-cell boost might drive stronger responses.

[Jim Strattman @jstrattman]

@ThomasOwenMcCa1 @KatStryker111 @kshaughnessy2 @NorthwestBio @LisainNJUSA @ElvirPons @nytimes @ABC @nymagPR @TheLastWord Griffin gave $125 million to the University of Chicago in 2017. It is true that everything and everyone can be bought for a price. https://t.co/YpYEgg2zFm

[Jim Strattman @jstrattman]

@CscottLawyer @LeahDavis199340 Just: “we do not comment on the regulatory review process or their deliberations or our interactions with them”

[Jim Strattman @jstrattman]

@CscottLawyer @LeahDavis199340 The company confirmed to me directly that a material event that would require an announcement is a denial or approval of the application and they will not disclose whether or not they continue to receive RFIs and questions.